Overview


Synthetic mRNA, or messenger RNA, is an RNA molecule artificially created in a laboratory setting. It is designed to imitate the natural mRNA found in cells. mRNA plays an important role in the process of protein synthesis within cells. In the context of biotechnology and medicine, synthetic mRNA has gained significant attention due to its potential applications, particularly in the development of vaccines. For instance, the Pfizer-BioNTech and Moderna COVID-19 vaccines are examples of mRNA vaccines. Scientists design a synthetic mRNA sequence that encodes a specific part of the target pathogen (like a virus). The advantage of synthetic mRNA technology is its versatility. It allows for the rapid development of vaccines against a wide range of pathogens as long as the genetic sequence of the target antigen is known. Also, because synthetic mRNA vaccines do not use live or inactivated pathogens, there's no risk of causing the disease.

Synthetic mRNA is categorized into different types based on its characteristics and purposes. IVT mRNA is created outside a living cell, usually in a laboratory. It involves the synthesis of mRNA molecules from a DNA template using an enzyme called RNA polymerase. IVT mRNA is widely used in research and the development of mRNA-based therapies. Self-amplifying mRNA is a special type of mRNA engineered to replicate itself once it enters a cell. This means that a small amount of SAM can generate a larger quantity of functional mRNA, potentially leading to a more robust and sustained protein production in target cells. Modified mRNA refers to synthetic mRNA that has been altered from its natural form to enhance stability, translation efficiency, or other desired properties. Modifications can include nucleotide changes or adding chemical groups to improve their performance in cellular environments. Long synthetic RNA can be designed for various purposes, including as templates for protein synthesis, functional RNA elements, or as research tools in molecular biology.

FutureWise Market Research has published a report that provides an insightful analysis synthetic mRNA market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts synthetic mRNA market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Nutcracker
  • Integrated DNA Technologies Inc.
  • ThermoFisher Scientific Inc.
  • Agilent Technologies Inc.
  • Bio-Synthesis Inc
  • Aldevron LLC
  • TriLink Biotechnologies Inc.
  • Moderna
  • BioNTech
  • CureVac
  • Translate Bio
  • Arcturus Therapeutics
  • Ethris
  • eTheRNA immunotherapies
  • Gritstone Oncology
  • GenScript Biotech Corporation
  • Tiba Biotechnology
  • CRISPR Therapeutics
  • Sangamo Therapeutics
  • Precision BioSciences
  • Intellia Therapeutics
  • Editas Medicine

(Note: The list of the major players will be updated with the latest market scenario and trends)

The increasing promise of mRNA technology in personalized medicine derives from its unique ability to harness the body's cellular machinery to produce specific proteins or antigens. By tailoring mRNA sequences to an individual's genetic profile, it is possible to design highly precise therapies targeting specific conditions or diseases. This potential breakthrough could revolutionize treatment strategies, offering patients therapies that are highly effective and minimally invasive, with the potential to improve outcomes and quality of life for a wide range of medical conditions. This level of customization represents a significant advancement in medical science, heralding a new era of patient-centric care. Moreover, mRNA technology's rapid and cost-effective production is a game-changer in biologics. Unlike traditional approaches that rely on cultivating live cells or organisms, mRNA vaccines and therapies are synthetically produced, streamlining the manufacturing process. This eliminates the need for complex and time-consuming cell culture techniques, reducing production timelines. Additionally, the scalability and standardized nature of mRNA synthesis enable large-scale manufacturing with relative ease. These advantages not only expedite response to emerging threats like pandemics but also have the potential to make therapies more accessible and affordable, therefore driving the synthetic mRNA market over the projection period. However, the stringent cold chain requirements for certain mRNA vaccines, exemplified by the Pfizer-BioNTech vaccine, present a significant logistical hurdle. Maintaining temperatures as low as -70 degrees Celsius demands specialized storage infrastructure and reliable refrigeration systems, which might be prohibitively expensive and technologically demanding, particularly for resource-constrained regions. This poses a considerable challenge in distributing vaccines to remote or developing areas with limited access to such sophisticated facilities, further hindering the growth of the synthetic mRNA market.

By Type

  • In vitro transcribed mRNA (IVT mRNA)
  • Self-amplifying mRNA (SAM)
  • Modified mRNA
  • Long synthetic RNA
  • Others

By Delivery Method

  • Lipid nanoparticles
  • Electroporation
  • Microinjection
  • Gene gun
  • Others

By Application

  • Therapeutics
    • Oncology
    • Infectious Diseases
    • Rare Genetic Diseases
    • Others
  • Vaccines
  • Research

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is driven by factors including the growing adoption of gene therapies, rising prevalence of chronic and genetic ailments, developing healthcare infrastructure, escalating demand for personalized cancer vaccines, and technological advancements in the field, which are the primary factors boosting the market growth. Furthermore, stringent regulatory standards, increasing R&D activities in the field, increasing healthcare spending, and the presence of favorable medical reimbursement scenarios across various regions are creating lucrative opportunities for market expansion. Also, increased partnerships and collaborations between companies, research institutions, and government agencies are further driving the growth of the market in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Synthetic mRNA Market By Type, By Delivery Method, By Application, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Synthetic mRNA Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Synthetic mRNA Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Synthetic mRNA Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Synthetic mRNA Market, By Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. In vitro transcribed mRNA (IVT mRNA)
        2. Self-amplifying mRNA (SAM)
        3. Modified mRNA
        4. Long synthetic RNA
        5. Others

  • 8.  Synthetic mRNA Market, By Delivery Method Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Lipid nanoparticles
        2. Electroporation
        3. Microinjection
        4. Gene gun
        5. Others

  • 9.  Synthetic mRNA Market, By Application Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Therapeutics
           1.1. Oncology
           1.2. Infectious Diseases
           1.3. Rare Genetic Diseases
           1.4. Others
        2. Vaccines
        3. Research

  • 10.  North America Synthetic mRNA Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.  Latin America Synthetic mRNA Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.  Europe Synthetic mRNA Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.  Asia Pacific Synthetic mRNA Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 14.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Nutcracker
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Integrated DNA Technologies Inc.
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. ThermoFisher Scientific Inc.
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Agilent Technologies Inc.
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Bio-Synthesis Inc
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Aldevron LLC
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. TriLink Biotechnologies Inc.
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Moderna
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. BioNTech
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. CureVac
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Translate Bio
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Arcturus Therapeutics
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Ethris
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. eTheRNA immunotherapies
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. Gritstone Oncology
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview
        16. GenScript Biotech Corporation
           16.1. Company Overview
           16.2. Product Portfolio
           16.3. SWOT Analysis
           16.4. Financial Overview
           16.5. Strategic Overview
        17. Tiba Biotechnology
           17.1. Company Overview
           17.2. Product Portfolio
           17.3. SWOT Analysis
           17.4. Financial Overview
           17.5. Strategic Overview
        18. CRISPR Therapeutics
           18.1. Company Overview
           18.2. Product Portfolio
           18.3. SWOT Analysis
           18.4. Financial Overview
           18.5. Strategic Overview
        19. Sangamo Therapeutics
           19.1. Company Overview
           19.2. Product Portfolio
           19.3. SWOT Analysis
           19.4. Financial Overview
           19.5. Strategic Overview
        20. Precision BioSciences
           20.1. Company Overview
           20.2. Product Portfolio
           20.3. SWOT Analysis
           20.4. Financial Overview
           20.5. Strategic Overview
        21. Intellia Therapeutics
           21.1. Company Overview
           21.2. Product Portfolio
           21.3. SWOT Analysis
           21.4. Financial Overview
           21.5. Strategic Overview
        22. Editas Medicine
           22.1. Company Overview
           22.2. Product Portfolio
           22.3. SWOT Analysis
           22.4. Financial Overview
           22.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients